|
|
|
|
|
Market Research Report
Pharmaceutical Pricing, Reimbursement, and Market Access News in the Fourth Quarter of 2009
|
Pharmaceutical Pricing, Reimbursement, and Market Access News in the Fourth Quarter of 2009 published by Decision Resources, Inc. in January, 2010. This report consists of 30 Pages and the price starts from US $ 4600.
Abstract
Introduction:
The fourth quarter of 2009 left drug manufacturers with many unanswered
questions that will have a major bearing on the future direction of the
pharmaceutical industry. The steady progress of healthcare reform legislation
in the United States was thrown into disarray by defeat for the Democrats in a
Senate special election in Massachusetts. European governments struggled to
find new ways to strike a balance between containing costs and promoting
access to innovative medicines. The Japanese government prepared for scheduled
price revisions in April 2010 while continuing to evaluate an industry
proposal for reform of the pricing and reimbursement system.
Questions Answered in This Report:
- In the United States, an unexpected electoral setback for the Democrats
threatens to derail the passage of legislation that would bring about the most
radical transformation of the U.S. healthcare system since the introduction of
Medicare and Medicaid in 1965. What are the key similarities and
differences between the bills drafted by the Senate and the House of
Representatives? What contributions are likely to be expected from the
pharmaceutical industry, and why have drug manufacturers been criticized for
their recent pricing policies? What are the potential repercussions of the
election result?
- European governments continue to focus on reference pricing and boosting
the use of generics to contain pharmaceutical expenditures. What are the
prospective changes for the German and Spanish reference pricing systems? How
do the French and U.K. governments intend to stimulate greater use of
generics?
- The German pharmaceutical market faces the prospect of significant changes
in the near future. What are the healthcare priorities of the new German
government? What is the outlook for health technology assessment in Germany?
What question has been raised with regard to rebate contracts?
- The United Kingdom has gone from being one of the highest-priced
pharmaceutical markets in Europe to the lowest-priced market in Europe.
What are the reasons for this dramatic change? How has the decline of U.K.
prices relative to prices in other European markets influenced parallel trade
patterns and affected pharmaceutical supply in the United Kingdom?
- Japan is scheduled to conduct its next biennial price revision in April
2010. What is the likely level of average price cuts? How will price cuts
for long-listed drugs, a new price premium for the development of new drugs,
and elimination of off-label drug use impact the Japanese pharmaceutical
industry?
Scope:
- Issues affecting the pharmaceutical industry in the United States:
healthcare reform; price increases; healthcare expenditure trends.
- Issues affecting the pharmaceutical industry in Europe: changes in
German healthcare policy; new cost-containment strategy in France;
modifications to the German and Spanish reference pricing systems; initiatives
to stimulate greater use of generics in France and the United Kingdom; outlook
for health economic evaluation in Germany.
- Issues affecting the pharmaceutical industry in Japan: results of
the most recent review of Japanese prices in preparation for the next biennial
price revision in April 2010; prospects for price maintenance system proposed
by the pharmaceutical industry.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- United States
- Uncertain Prospects for Healthcare Reform
- Renewed Criticism of Rising Drug Prices
- Slowdown in the Growth Rate of National Healthcare Expenditures
- France
- New Cost-Containment Measures for 2010
- New Targets for Generics Dispensing
- Germany
- Healthcare Priorities of New Government
- Outlook for Health Economic Evaluation
- Questions Regarding the Future of Rebate Contracts
- Prospective Reductions to Many Reference Prices
- Italy
- Variable Access to Innovative Medicines Across Italy
- Spain
- Changes to the Reference Pricing System
- United Kingdom
- Sharp Decline in U.K. Prices Relative to Prices in Other Major Markets
- Growing Concern at the Impact of Parallel Exports
- Initiatives to Increase the Use of Generics
- Japan
- Prospective Average Price Cut of 6.4% in April 2010
- Introduction of a Premium for the Development of New Drugs and
Elimination of Off-Label Drug Use
- Outlook and Implications for the Pharmaceutical Industry
Tables
- 1. Key Features of Healthcare Reform Bills in the U.S. Senate and House of
Representatives
Figures
- 1. Prescription Drug Expenditures and Spending Growth Rate in the United
States in Select Years, 2000-2008
- 2. Targeted Generics Dispensing Rates for Key Compounds in France, 2010
- 3. Average Branded Drug Prices in Major Markets as a Percentage of U.K.
Prices, 2004-2008
- 4. Average Biennial Price Revisions in Japan, 1994-2008
- 5. Price Adjustment Range in Japan, 1994-2008
|
 |
